PARP and Cancer - If It's Broke, Don't Fix It.

被引：34

作者：

Carey, Lisa A. ^{[1
]}

Sharpless, Norman E.

机构：

[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Dept Med, Chapel Hill, NC 27599 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2011年 / 364卷 / 03期

关键词：

POLY(ADP-RIBOSE); POLYMERASE;

D O I：

10.1056/NEJMe1012546

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：277 / 279

页数：3

共 10 条

[1] PARP1 deficiency exacerbates diet-induced obesity in mice [J].

Devalaraja-Narashimha, Kishor ;

Padanilam, Babu J. .

JOURNAL OF ENDOCRINOLOGY, 2010, 205 (03) :242-251

[2] Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].

Farmer, H ;

McCabe, N ;

Lord, CJ ;

Tutt, ANJ ;

Johnson, DA ;

Richardson, TB ;

Santarosa, M ;

Dillon, KJ ;

Hickson, I ;

Knights, C ;

Martin, NMB ;

Jackson, SP ;

Smith, GCM ;

Ashworth, A .

NATURE, 2005, 434 (7035) :917-921

[3] Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. [J].

Fong, Peter C. ;

Boss, David S. ;

Yap, Timothy A. ;

Tutt, Andrew ;

Wu, Peijun ;

Mergui-Roelvink, Marja ;

Mortimer, Peter ;

Swaisland, Helen ;

Lau, Alan ;

O'Connor, Mark J. ;

Ashworth, Alan ;

Carmichael, James ;

Kaye, Stan B. ;

Schellens, Jan H. M. ;

de Bono, Johann S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :123-134

[4] Triple-Negative Breast Cancer [J].

Foulkes, William D. ;

Smith, Ian E. ;

Reis-Filho, Jorge S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20) :1938-1948

[5] Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer [J].

Gelmon, K. A. ;

Hirte, H. W. ;

Robidoux, A. ;

Tonkin, K. S. ;

Tischkowitz, M. ;

Swenerton, K. ;

Huntsman, D. ;

Carmichael, J. ;

Macpherson, E. ;

Oza, A. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[6] Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics [J].

He, Jin-xue ;

Yang, Chun-hao ;

Miao, Ze-hong .

ACTA PHARMACOLOGICA SINICA, 2010, 31 (09) :1172-1180

[7] A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. [J].

Isakoff, S. J. ;

Overmoyer, B. ;

Tung, N. M. ;

Gelman, R. S. ;

Giranda, V. L. ;

Bernhard, K. M. ;

Habin, K. R. ;

Ellisen, L. W. ;

Winer, E. P. ;

Goss, P. E. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[8] The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets [J].

Krishnakumar, Raga ;

Kraus, W. Lee .

MOLECULAR CELL, 2010, 39 (01) :8-24

[9] Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer. [J].

O'Shaughnessy, Joyce ;

Osborne, Cynthia ;

Pippen, John E. ;

Yoffe, Mark ;

Patt, Debra ;

Rocha, Christine ;

Koo, Ingrid Chou ;

Sherman, Barry M. ;

Bradley, Charles .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (03) :205-214

[10] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial [J].

Tutt, Andrew ;

Robson, Mark ;

Garber, Judy E. ;

Domchek, Susan M. ;

Audeh, M. William ;

Weitzel, Jeffrey N. ;

Friedlander, Michael ;

Arun, Banu ;

Loman, Niklas ;

Schmutzler, Rita K. ;

Wardley, Andrew ;

Mitchell, Gillian ;

Earl, Helena ;

Wickens, Mark ;

Carmichael, James .

LANCET, 2010, 376 (9737) :235-244

← 1 →